CervoMed Inc. - Common Stock CRVO 深 沪
交易中 09-03 11:39:49 美东时间
10.80
+0.705
+6.98%
华盛通- 最 高10.89
- 今 开10.20
- 成交量 10.58万股
- 最 低 10.19
- 昨 收 10.095
- 总市值 9398.92万
- 52周最高 19.50
- 市盈率 静 --
- 换手率 1.22%
- 52周最低 1.80
- 委 比 -68.54%
- 总股本 870.27万
- 历史最高 17437.50
- 量 比 4.45
- 振 幅 6.93%
- 历史最低 1.80
- 每 手 1
- 风险率 4.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. announced that its management will participate in two investor conferences in September 2025: the H.C. Wainwright 27th Annual Global Investment Conference on September 8, featuring a presentation and 1x1 investor meetings, and Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, focusing on 1x1 investor meetings. CervoMed, a clinical-stage company developing treatments for age-related neurologic disorders, ...
今天 12:00
D. Boral Capital Maintains Buy on CervoMed, Raises Price Target to $31
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $31.
08-18 19:45
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Chardan Capital Maintains Buy on CervoMed, Maintains $15 Price Target
Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $15 price target.
08-11 19:46
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
CervoMed reported positive data from the Phase 2b RewinD-LB Trial, showing that neflamapimod significantly reduced clinical worsening in Dementia with Lewy Bodies (DLB) patients, particularly in those with minimal Alzheimer’s co-pathology. The treatment also decreased biomarkers of neurodegeneration. The company plans to meet with the FDA in Q4 2025 to discuss Phase 3 trial design. Financially, CervoMed ended Q2 2025 with $33.5M in cash and repor...
08-11 12:00
CervoMed Q2 EPS $(0.70) Misses $(0.63) Estimate, Sales $1.758M Beat $1.734M Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.63) by 11.11 percent. This is a 159.26 percent decrease over losses of $(0.27) per share from the
08-08 21:57
CervoMed Shares Business and Financial Updates Online
CervoMed ( ($CRVO) ) has issued an announcement. CervoMed Inc. has made availab...
08-06 04:50
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference
CervoMed Inc. (NASDAQ: CRVO) announced that its management will participate in a fireside chat and investor meetings at the CG 45th Annual Growth Conference in Boston from August 12 to 14, 2025. The fireside chat will take place on August 12 at 2:00 PM ET and can be accessed via a webcast link on the CervoMed website. The company, focused on developing treatments for age-related neurologic disorders, is currently evaluating neflamapimod, an inves...
08-05 12:00
CervoMed's Dementia Data Show Slowed Disease Progression
CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good tolerability.
07-28 23:20
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
CervoMed Inc. announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial, showing that oral neflamapimod reduced the risk of clinically significant worsening by 54% (p=0.0037) and 64% (p=0.0001) in patients with minimal evidence of AD co-pathology. This decrease was observed in patients with ptau181 < 2.2 pg/mL. Additionally, neflamapimod demonstrated a significant reduction in plasma levels of GFAP, a biomarker of n...
07-28 11:00
